Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Axon Therapies, Inc.
Study ID
NCT04592445
Status
Recruiting

Conditions

  • Heart Failure With Preserved Ejection Fraction (HFpEF

Eligibility Criteria

Sex
ALL
Age
40 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Greater Splanchnic Nerve Ablation — DEVICE
    The greater splanchnic nerve (GSN) ablation procedure begins with a small needle puncture in the groin or neck to access a vein, using methods that are commonly used for heart procedures. Doctors then guide thin tubes and wires through the vein to reach a nerve called the right greater splanchnic nerve. X-ray imaging is used to help the doctor see where the catheter is and guide it to the correct location. Once the catheter is in the right place, the doctor uses the device to treat the nerve using controlled heat.
  • Sham Control — DEVICE
    During the sham procedure, a small needle puncture will be made in the groin or neck to access a vein using standard medical techniques. A short tube will be placed into the vein, similar to what is done for many heart procedures. The Satera catheter and treatment devices will not be inserted, and the nerve will not be treated. The procedure will take about the same amount of time as the treatment procedure.

Study Details

The purpose of this clinical study is to evaluate the safety and early effectiveness of a catheter-based procedure that treats a nerve called the right greater splanchnic nerve. The study includes people who have heart failure with preserved ejection fraction (HFpEF). The goal is to learn whether this procedure, performed using the Satera Ablation System, may help improve symptoms and to better understand which patients may benefit most from this treatment in the future.

Key Dates

Start date
Dec 18, 2020
Status verified
Mar 2026
Primary completion
Jan 10, 2028
Completion
Aug 10, 2029

Study Design

Enrollment
150 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Greater Splanchnic Nerve Ablation
    After anesthesia is given, doctors will use the Satera Ablation System to reach a nerve called the right greater splanchnic nerve. Subjects receive catheter-based unilateral ablation of the right greater splanchnic nerve.
  • Sham Comparator: Sham Control Arm
    After anesthesia is given, doctors will place a small tube into a vein. The steps and length of the procedure will be similar to the Axon treatment procedure, but the study treatment will not be performed.

Primary Outcome Measure

Primary Safety Endpoint: Device or procedure related serious adverse events [ Time Frame: 1 Month ]

Central Contacts

Locations (20)

FacilityCityStateZIPSite coordinators
Cardiology PCBirminghamAlabama35211-
Arizona Cardiovascular Research CenterPhoenixArizona85016-
Scripps HealthLa JollaCalifornia92037-
University of California, San FranciscoSan FranciscoCalifornia94143
Priscilla Zhang
415-514-7903
Liviu Klein, MD (PRINCIPAL_INVESTIGATOR)
Bluhm Cardiovascular Institute of Northwestern UniversityChicagoIllinois60611
Daniel Roshevsky
Ravi Patel, MD (PRINCIPAL_INVESTIGATOR)
University of Chicago Medical CenterChicagoIllinois60637
Adaeze Emeka
Mark Nathan Belkin, MD (PRINCIPAL_INVESTIGATOR)
Prairie Education and Research CooperativeSpringfieldIllinois62701-
Ascension St. Vincent - Cardiovascular Research InstituteIndianapolisIndiana46260-
Cardiovascular Institute of the SouthHoumaLouisiana70360
Kimberly Lirette
Peter Fail, MD (PRINCIPAL_INVESTIGATOR)
Michigan Medicine, University of MichiganAnn ArborMichigan48109
Scott Hummel, MD (PRINCIPAL_INVESTIGATOR)
Mayo ClinicRochesterMinnesota55905
Alyssa Ploof
Barry Borlaug, MD (PRINCIPAL_INVESTIGATOR)
St. Louis Heart and VascularSt LouisMissouri63136
Melissa McCann
Gil Vardi, MD (PRINCIPAL_INVESTIGATOR)
Columbia University Medical CenterNew YorkNew York10032
Nir Uriel, MD (PRINCIPAL_INVESTIGATOR)
Icahn School of Medicine at Mount SinaiNew YorkNew York10029-
Weill Cornell MedicineNew YorkNew York10021
Caroline Goldstein
Parag Goyal, MD (PRINCIPAL_INVESTIGATOR)
Rochester General HospitalRochesterNew York14621
Kathleen Ebeling, RN
Scott Feitell, DO (PRINCIPAL_INVESTIGATOR)
Duke University Medical CenterDurhamNorth Carolina27710
Matthew Gray
Marat Fudim, MD, MHS (PRINCIPAL_INVESTIGATOR)
Ohio State University Wexner Medical CenterColumbusOhio43210
Kalyn Ferguson
Alexandria Miller, MD (PRINCIPAL_INVESTIGATOR)
Medical University of South CarolinaCharlestonSouth Carolina29425
Elly Borhanian
Sheldon Litwin, MD (PRINCIPAL_INVESTIGATOR)
Virginia Commonwealth University Medical CenterRichmondVirginia23298-

Find similar trials in Birmingham, AL